Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Analog Mid Mixture;   Drug: Basal Insulin Analog
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified January 2017

Determination of Cut-off Value of AGEsP and HbA1c in Type 2 Diabetes Diagnosis in China

Condition:   Type II Diabetes
Intervention:   Device: syringe, fundus camera etc
Sponsor:   Zhongda Hospital
Active, not recruiting - verified January 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified January 2017

TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

Conditions:   Diabetes Mellitus;   Alzheimer Dementia
Intervention:   Drug: 18F-THK-5351
Sponsors:   Columbia University;   National Institute on Aging (NIA)
Not yet recruiting - verified January 2017

Frequency of Hypoglycemia in Patients With Type 2 Diabetes Under Insulin Therapy Older Than 75 Years in Real Life

Conditions:   Type2 Diabetes;   Elderly;   Hypoglycemia
Intervention:   Device: glycemic sensor FREESTYLE Libre
Sponsor:   Nantes University Hospital
Not yet recruiting - verified January 2017

A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide;   Drug: BIAsp30;   Drug: Metformin
Sponsor:   First Hospital of Jilin University
Not yet recruiting - verified January 2017

DD2-Coronary Plaque Morphology and Plaque Progression

Conditions:   Diabetes;   Plaque;   Atherosclerosis
Intervention:   Radiation: Cardiac CT
Sponsors:   Sydvestjysk Hospital;   The Danish Diabetes Academy supported by the Novo Nordisk Foundation;   University of Southern Denmark;   Department of Regional Health Research - Center Southwest;   Edith and Vagn Hedegaard Jensens Foundation;   Karola Jørgensens Foundation and Foundation for Cardiology in Southwest Denmark.
Active, not recruiting - verified January 2017

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Interventions:   Drug: Trelagliptin;   Drug: Daily DPP-4 inhibitor
Sponsor:   Takeda
Recruiting - verified January 2017

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified January 2017

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

Glargine U300 Hospital Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Glargine U300;   Drug: Glargine U100;   Drug: Glulisine Insulin
Sponsor:   Emory University
Not yet recruiting - verified January 2017

A Mobile Phone-based Program for Adults With Prediabetes

Conditions:   Prediabetic State;   Diabetes Mellitus
Intervention:   Device: JOOL Health Mobile Phone Application
Sponsors:   University of Michigan;   Blue Cross Blue Shield of Michigan Foundation
Not yet recruiting - verified January 2017

A Holistic Dietary Intervention for Persons With Spinal Cord Injury

Condition:   Spinal Cord Injuries
Intervention:   Behavioral: A holistic dietary intervention for persons with spinal cord injury
Sponsor:   Hanne Bjørg Slettahjell
Active, not recruiting - verified January 2017

Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.

Conditions:   Type2 Diabetes;   Atherosclerosis;   Plaque, Atherosclerotic;   Plaque Vulnerability;   Diabetes Complications;   Microalbuminuria;   Coronary Computed Tomography Angiography
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified January 2017

The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes

Conditions:   Endothelial Dysfunction;   Insulin Resistance
Intervention:   Drug: Eplerenone
Sponsor:   University of Southern Denmark
Recruiting - verified January 2017

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Conditions:   Diabetic Non-proliferative Retinopathy;   Type2 Diabetes
Interventions:   Drug: Tangwang prescription;   Drug: Placebo
Sponsors:   Fengmei Lian;   Guang'anmen Hospital of China Academy of Chinese Medical Sciences;   The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine;   Hubei Hospital of Traditional Chinese Medicine;   Zhengzhou City Hospital of Traditional Chinese Medicine;   Baodin City Hospital of Traditional Chinese Medicine;   zi bo wanjie cancer hospital;   Shijiazhuang City Hospital of Traditional Chinese Medicine;   Zouping Country Hospital of Traditional Chinese Medicine
Not yet recruiting - verified January 2017

Heidelberg Study on Diabetes and Complications

Condition:   Diabetes Complications
Intervention:   Other: No interventions are planned for this study.
Sponsor:   Heidelberg University
Recruiting - verified January 2017

Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Exenatide;   Drug: Placebos
Sponsors:   Filip Krag Knop;   Steno Diabetes Center
Recruiting - verified January 2017

Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type II;   Hypoglycemia;   Cognitive Change
Interventions:   Other: Hypoglycaemic clamp;   Other: Euglycaemic clamp
Sponsors:   Bispebjerg Hospital;   University Hospital, Gentofte, Copenhagen;   Psychiatric Centre Rigshospitalet
Not yet recruiting - verified January 2017

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Placebo drug that simulates Irbesartan tablets;   Drug: irbesartan tablets;   Drug: Placebo drug that simulates HuangKui capsule;   Drug: HuangKui Capsule
Sponsor:   Jiangsu Famous Medical Technology Co., Ltd.
Not yet recruiting - verified December 2016

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Coronary Artery Disease
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Athens
Recruiting - verified January 2017

Lowering Impaired Fasting Glucose Levels With Exercise

Condition:   Type2 Diabetes
Interventions:   Behavioral: No exercise;   Behavioral: Morning exercise;   Behavioral: Evening exercise
Sponsor:   University of Missouri-Columbia
Recruiting - verified January 2017

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified January 2017

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Conditions:   Diabetes;   Cardiovascular Disease
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   St. Michael's Hospital, Toronto;   Boehringer Ingelheim (Canada) LTD
Not yet recruiting - verified January 2017

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified January 2017

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified January 2017

Study With Dapagliflozin

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified January 2017

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified January 2017

Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time

Condition:   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified January 2017

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: midazolam;   Drug: metoprolol
Sponsor:   Sanofi
Completed - verified January 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Drug-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified January 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified January 2017

Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes

Condition:   Diabetes Mellitus
Intervention:   Other: PATH electronic decision support tool
Sponsors:   St Elizabeth Healthcare;   Eilerman Endocrinology & Magnolia Associates
Recruiting - verified January 2017

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Conditions:   Poor Glycemic Control;   Cardiovascular Risk Factors;   Cognitive Function 1, Social
Interventions:   Dietary Supplement: carnosine;   Drug: Placebo
Sponsor:   Monash University
Recruiting - verified January 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Conditions:   Type 2 Diabetes Mellitus;   Heart Failure
Interventions:   Drug: Saxagliptin;   Drug: Sitagliptin;   Drug: Placebo to match saxagliptin;   Drug: Placebo to match sitagliptin
Sponsor:   AstraZeneca
Recruiting - verified January 2017

Pilot Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Economic incentive;   Behavioral: Partner support;   Behavioral: Mixed incentives
Sponsors:   Universidad Peruana Cayetano Heredia;   Johns Hopkins School of Public Health
Active, not recruiting - verified January 2017

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Low intensity therapeutic ultrasound
Sponsor:   Universidade Federal de Santa Maria
Recruiting - verified January 2017

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Drug: Insulin glargine;   Drug: Non-insulin antihyperglycemic drugs
Sponsor:   Sanofi
Recruiting - verified January 2017

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

Complement and Cardiovascular Risk in Adolescents

Conditions:   Cardiovascular Disease;   Type 2 Diabetes
Intervention:  
Sponsors:   Ohio State University;   American Heart Association
Recruiting - verified January 2017

Pediatric Obesity and the Infant Microbiome

Condition:   Pediatric Obesity
Intervention:  
Sponsor:   University of Florida
Not yet recruiting - verified January 2017

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Completed - verified January 2017

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified January 2017

A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease

Condition:   Diabetic Chronic Kidney Disease
Intervention:   Biological: Neo-Kidney Augment (NKA)
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Recruiting - verified January 2017

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2017

The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis

Conditions:   Rheumatoid Arthritis;   Physical Activity
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Siobhan Graham;   University of Bath
Completed - verified January 2017

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified January 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified January 2017

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrake

Condition:   Diabetes Mellitus, Type 2
Intervention:   Dietary Supplement: AphoelineBrake
Sponsors:   Dasman Diabetes Institute;   University at Buffalo
Recruiting - verified December 2016

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Conditions:   Osteoarthritis of the Knee;   Type 2 Diabetes Mellitus
Interventions:   Drug: FX006 40 mg;   Drug: TCA IR 40 mg
Sponsor:   Flexion Therapeutics, Inc.
Completed - verified January 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified January 2017

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified January 2017

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Recruiting - verified January 2017

Emotional Disorders and Outcomes in Adults With Type 2 Diabetes Mellitus at Primary Care

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Universiti Putra Malaysia;   Ministry of Health, Malaysia;   UMC Utrecht
Completed - verified January 2017

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin placebo
Sponsors:   AstraZeneca;   Parexel;   Q2 solutions;   PRA Health Sciences;   Covance Laboratories, Inc
Recruiting - verified January 2017

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified January 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified January 2017

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin L-proline;   Drug: Metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Active, not recruiting - verified January 2017

Prebiotic in Preventing Low Birth Weight

Conditions:   Birth Weight <2500gm;   Genitourinary Tract Infection
Interventions:   Dietary Supplement: Fructooligosaccharide;   Dietary Supplement: Pocari-Sweat
Sponsors:   International Centre for Diarrhoeal Disease Research, Bangladesh;   Karolinska Institutet;   Swedish International Development Cooperation Agency (SIDA)
Recruiting - verified December 2016

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No Intervention
Sponsor:   Janssen Inc.
Active, not recruiting - verified January 2017

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2017

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2017

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2017

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2017

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type2 Diabetes Mellitus;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2017

The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk

Condition:   Insulin Sensitivity
Interventions:   Dietary Supplement: carnosine;   Other: Placebo
Sponsor:   Monash University
Not yet recruiting - verified January 2017

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TTP273;   Drug: Placebo
Sponsor:   vTv Therapeutics
Completed - verified January 2017

Vaccine Efficacy in Diabetic and Elderly Patients

Condition:   Inflammation
Intervention:   Biological: Influenza Virus Vaccine
Sponsors:   Tulane University;   Louisiana Clinical and Translational Science Center
Completed - verified January 2017

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2017

Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Intervention:   Biological: MNCs
Sponsor:   Postgraduate Institute of Medical Education and Research
Completed - verified January 2017

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Recruiting - verified January 2017

Metabolic Effects of Angiotensin-(1-7)

Conditions:   Obesity;   Insulin Resistance;   Hypertension;   Metabolic Cardiovascular Syndrome
Interventions:   Drug: Angiotensin-(1-7);   Drug: Saline
Sponsor:   Vanderbilt University
Recruiting - verified January 2017

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: DS-8500a;   Drug: Sitagliptin;   Drug: placebo
Sponsor:   Daiichi Sankyo Co., Ltd.
Completed - verified January 2017

Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Standard of Care
Sponsors:   AstraZeneca;   Quintiles, Inc.;   Clinical Practice Research Datalink
Recruiting - verified January 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec;   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2017

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2017

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: saxagliptin;   Drug: AZD9668;   Drug: placebo
Sponsors:   Nick Giannoukakis, PhD;   National Institutes of Health (NIH);   University of Pittsburgh;   University of South Florida;   AstraZeneca
Recruiting - verified January 2017

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
Recruiting - verified January 2017

Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care Sector

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Shared care
Sponsors:   University Hospital, Gentofte, Copenhagen;   Metropolitan University College
Active, not recruiting - verified January 2017

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2017

NEPHSTROM for Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Biological: Mesenchymal Stromal Cells;   Other: Placebo
Sponsors:   Mario Negri Institute for Pharmacological Research;   Leiden University Medical Center;   ASST Papa Giovanni XXIII, Bergamo, Italy;   IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy;   Belfast Health and Social Care Trust;   National University of Ireland, Galway, Ireland;   University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK;   NHS Blood and Transplant
Not yet recruiting - verified January 2017

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Human regular U-500 insulin (CSII);   Drug: Human regular U-500 insulin (MDI)
Sponsors:   Eli Lilly and Company;   Insulet Corporation
Active, not recruiting - verified January 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Condition:   Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg;   Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Sponsor:   AstraZeneca
Recruiting - verified January 2017

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Diabetes Mellitus, Type 2
Interventions:   Drug: Biphasic Remogliflozin Etabonate;   Other: Placebo
Sponsors:   BHV Pharma;   Integrium
Completed - verified January 2017

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

Condition:   Type 1 Diabetes
Interventions:   Drug: Bromocriptine;   Other: Placebo
Sponsors:   University of Colorado, Denver;   Juvenile Diabetes Research Foundation
Recruiting - verified January 2017

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Intervention:   Biological: Neo-Kidney Augment
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Enrolling by invitation - verified January 2017

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2017

Neck Grasp as a Predictor of Sleep Apnea

Conditions:   Obstructive Sleep Apnea;   Type 2 Diabetes
Interventions:   Other: polysomnogram;   Other: home sleep test;   Other: Easy Sleep Apnea Predictor
Sponsor:   Bassett Healthcare
Completed - verified January 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified January 2017

Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting - verified January 2017

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified January 2017

Nicotinic Agonist Effects on BMI and Neuronal Response

Condition:   Obesity
Interventions:   Drug: DMXB-A;   Other: Placebo
Sponsor:   University of Colorado, Denver
Recruiting - verified January 2017

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

Conditions:   Tissue and Organ Harvesting;   Liver Transplantation;   Brain Death
Intervention:   Procedure: Fibroscan
Sponsor:   University Hospital, Limoges
Recruiting - verified January 2017

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2017

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified January 2017

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Regular Human Insulin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Novo Nordisk A/S;   Medtronic;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2017

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Suspended - verified January 2017

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Condition:   Physical Activity
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   Christopher Bell;   AstraZeneca
Recruiting - verified January 2017

Pharmacoepigenetics of Bipolar Disorder Treatment

Conditions:   Antipsychotic Agents;   Bipolar Disorder
Intervention:  
Sponsor:   Wayne State University
Recruiting - verified January 2017

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Sitagliptin-Placebo;   Drug: Glimepiride-Placebo
Sponsor:   GWT-TUD GmbH
Terminated - verified January 2017

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Recruiting - verified January 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Conditions:   Vascular Diseases;   Hypercholesterolemia;   Diabetes Mellitus
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Placebo product
Sponsors:   Unilever R&D;   CSIRO
Completed - verified January 2017

Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia

Conditions:   Type 1 Diabetes;   Nocturnal Hypoglycemia
Intervention:   Device: Hypo-Sense (non invasive sensor)
Sponsors:   Rabin Medical Center;   Night Sense Ltd
Completed - verified January 2017

Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)

Conditions:   Obesity;   Type 2 Diabetes
Intervention:  
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Sanford-Burnham Medical Research Institute
Completed - verified January 2017

Uncovering the 'ORIGINS' of Diabetes

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Florida Hospital;   Sanford-Burnham Medical Research Institute;   Children's Hospital & Research Center Oakland;   Duke Univeristy Sarah W. Stedman Nutrition & Metabolism Center
Completed - verified January 2017

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

Conditions:   Type 2 Diabetes;   Nonalcoholic Fatty Liver Disease;   Vitamin D Deficiency
Intervention:   Dietary Supplement: Ergocalciferol, placebo
Sponsor:   University of Massachusetts, Worcester
Completed - verified January 2017

Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test

Conditions:   Genetics;   Metabolism;   Type 2 Diabetes
Interventions:   Other: Mixed Meal Tolerance Test;   Drug: Metformin
Sponsors:   Massachusetts General Hospital;   Instituto Carlos Slim de la Salud;   Broad Institute
Recruiting - verified January 2017

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified January 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Recruiting - verified January 2017

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified November 2016

Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Condition:   Type II Diabetes Mellitus
Intervention:   Drug: Pioglitazone
Sponsor:   Takeda
Completed - verified January 2017

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Behavioral: No treatment given;   Behavioral: survey
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified January 2017

Exercise Resistance in Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Exercise
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   American Diabetes Association
Active, not recruiting - verified January 2017

Sunshine 2 Study for Women With Diabetes

Conditions:   Diabetes;   Depression;   Quality of Life
Interventions:   Drug: Vitamin D3;   Drug: Vitamin D3 comparator
Sponsors:   Loyola University;   National Institutes of Health (NIH);   National Institute of Nursing Research (NINR)
Recruiting - verified January 2017

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2017

Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix

Conditions:   Obesity;   Diet Therapy;   Diabetes Type 2
Intervention:   Behavioral: Controlling Gestational Weight Gain
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2016

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glipizide;   Drug: Metformin;   Other: Oral Glucose Tolerance Test
Sponsors:   Massachusetts General Hospital;   Brigham and Women's Hospital;   Joslin Diabetes Center;   Broad Institute
Active, not recruiting - verified January 2017

Type 2 Diabetes and Exercise Function in Single Leg Exercises

Condition:   Type 2 Diabetes
Intervention:   Other: Single Leg Exercise Training
Sponsor:   University of Colorado, Denver
Recruiting - verified January 2017

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Completed - verified January 2017

French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Biomarkers of Diabetic Retinopathy Progression

Conditions:   Type 2 Diabetes Mellitus;   Mild Nonproliferative Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting - verified January 2017

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic human insulin 30;   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Validation of Circulating Endothelial Cells and Microparticles in Youth

Conditions:   Childhood Obesity;   Bariatric Surgery Candidate
Intervention:  
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified January 2017

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

Conditions:   Intrahepatic Cholestasis of Pregnancy;   Gestational Diabetes Mellitus
Intervention:  
Sponsor:   Imperial College London
Recruiting - verified December 2016

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Association Pour la Recherche en Diabetologie et en Geriatrie;   Novo Nordisk A/S;   Umanis
Active, not recruiting - verified January 2017

Psoriasis Inflammation and Systemic Co Morbidities

Condition:   Psoriasis
Intervention:  
Sponsors:   Rockefeller University;   Weill Medical College of Cornell University
Active, not recruiting - verified January 2017

Study of the Potential of a Macronutrient Balanced Normocaloric Diet to Treat Lifestyle Diseases

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Cardiovascular Diseases
Interventions:   Dietary Supplement: Diet A;   Dietary Supplement: Diet B
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed - verified January 2017

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster-acting insulin aspart;   Drug: insulin aspart;   Drug: Faster-acting insulin aspart;   Drug: Faster-acting insulin aspart;   Drug: Faster-acting insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Biological: albiglutide;   Drug: sitagliptin
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Natural History of Autoimmune Diabetes and Its Complications

Conditions:   Type 1 Diabetes;   Type 2 Diabetes;   Immunologically Mediated Type 1 Diabetes;   Anti Beta-Cell Autoantibodies;   Autoimmunity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2016

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin aspart;   Drug: insulin detemir;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Conditions:   Diabetes;   Obesity;   Healthy Volunteers
Interventions:   Dietary Supplement: Vitamin E;   Dietary Supplement: Vitamin C
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2016

Acarbose Cardiovascular Evaluation Trial

Conditions:   Coronary Heart Disease;   Acute Coronary Syndrome;   Impaired Glucose Tolerance;   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Acarbose;   Drug: Matching Placebo
Sponsors:   University of Oxford;   Bayer
Active, not recruiting - verified January 2017

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: biphasic human insulin 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: insulin glargine;   Drug: insulin glulisine
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: biphasic insulin aspart 50;   Drug: biphasic insulin aspart 70
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified January 2017

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: insulin glargine;   Drug: metformin;   Drug: glimepiride
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: insulin NPH;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: insulin glargine;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: rosiglitazone maleate/metformin hydrochloride
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Rosiglitazone (BRL49653C)
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: placebo;   Drug: GSK376501
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: exenatide
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

Conditions:   Diabetes;   Diabetes Mellitus, Type 2;   Delivery Systems
Interventions:   Device: FlexPen®;   Device: vial and syringe
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

A New Oral Treatment For Type II Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GW0823093
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: pioglitazone;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Completed - verified January 2017

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: rosiglitazone/metformin
Sponsor:   GlaxoSmithKline
Completed - verified January 2017